LICC: L-BLP25 in Patients with Colorectal Cancer after resection of liver metastases - a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial

ABSTRACT: Primary objectives: Comparative evaluation of recurrence-free survival time and three year overall survial between the treatment groups L-BLP25 plus cyclophosphamide versus placebo vaccination and saline infusion Primary endpoints: Recurrence-Free Survival (RFS) time and three year overall survival based on standard imaging.

DISEASE(S): Colorectal Cancer Metastatic,Patients With Metastatic Colorectal Carcinoma (crc), Who Have Undergone A Complete Resection Of Their Primary Tumor And Recent Resection Of Their Liver Metastases (r0 Or R1) With Curative Intent.

PROVIDER: 2529185 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR